Abstract
Although grouped under the same name, neuroendocrine tumors comprise a heterogeneous family of neoplasms with a wide range of clinical and biological behaviors and responses to different treatment options. Most of the tumors derived from enterochromaffin cells are indolent or at least not as aggressive as epithelial tumors. However, a small percentage of these tumors have a poor prognosis and highly aggressive histology that results in a very short overall survival and scarce treatment options compared with well and moderately differentiated tumors. Patients with poorly differentiated neuroendocrine carcinomas barely exceed 6-8 months of survival. This particular poor risk subgroup of neuroendocrine tumors remains an unmet medical need and becomes a challenge in the daily clinical practice. A deeper knowledge of the biology and novel targeted agents might allow for future clinical development of novel agents in this setting. In this review we summarize the current background behind the management of poorly differentiated neuroendocrine carcinomas in daily clinical practice.
Keywords: Management, neuroendocrine tumors, poorly-differentiated, review.
Current Pharmaceutical Design
Title:A Comprehensive Review of Poorly Differentiated Neuroendocrine Carcinomas (pdNECs): a Niche to Find Novel Opportunities
Volume: 20 Issue: 42
Author(s): Pablo Reguera, Ainhoa Madariaga and Enrique Grande
Affiliation:
Keywords: Management, neuroendocrine tumors, poorly-differentiated, review.
Abstract: Although grouped under the same name, neuroendocrine tumors comprise a heterogeneous family of neoplasms with a wide range of clinical and biological behaviors and responses to different treatment options. Most of the tumors derived from enterochromaffin cells are indolent or at least not as aggressive as epithelial tumors. However, a small percentage of these tumors have a poor prognosis and highly aggressive histology that results in a very short overall survival and scarce treatment options compared with well and moderately differentiated tumors. Patients with poorly differentiated neuroendocrine carcinomas barely exceed 6-8 months of survival. This particular poor risk subgroup of neuroendocrine tumors remains an unmet medical need and becomes a challenge in the daily clinical practice. A deeper knowledge of the biology and novel targeted agents might allow for future clinical development of novel agents in this setting. In this review we summarize the current background behind the management of poorly differentiated neuroendocrine carcinomas in daily clinical practice.
Export Options
About this article
Cite this article as:
Reguera Pablo, Madariaga Ainhoa and Grande Enrique, A Comprehensive Review of Poorly Differentiated Neuroendocrine Carcinomas (pdNECs): a Niche to Find Novel Opportunities, Current Pharmaceutical Design 2014; 20 (42) . https://dx.doi.org/10.2174/1381612820666140826154033
DOI https://dx.doi.org/10.2174/1381612820666140826154033 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Dark Side of Stem Cells: Triggering Cancer Progression by Cell Fusion
Current Molecular Medicine Combined Treatment with CCI779 and SB203580 Induces Cellular Senescence in Renal Cell Carcinoma Cell Line via p53 Pathway
Anti-Cancer Agents in Medicinal Chemistry Spectrum of Radiopharmaceuticals in Nuclear Oncology
Current Cancer Drug Targets Cancer Drug Development Using Glucose Metabolism Radiopharmaceuticals
Current Pharmaceutical Design Clinical Pharmacogenetics of Methotrexate
Current Drug Metabolism Connecting A Tumor to the Environment
Current Pharmaceutical Design Anticancer Vitamin K3 Analogs: A Review
Anti-Cancer Agents in Medicinal Chemistry Identification of Three Differentially Expressed miRNAs as Potential Biomarkers for Lung Adenocarcinoma Prognosis
Combinatorial Chemistry & High Throughput Screening Safety of Multi-Targeted Kinase Inhibitors as Monotherapy Treatment of Cancer: A Systematic Review of the Literature
Current Drug Safety Oncogenic Signalling Networks and Polypharmacology as Paradigms to Cope with Cancer Heterogeneity
Current Proteomics The Role of Oxidative Stress Modulators in Breast Cancer
Current Medicinal Chemistry Central Nervous System Abnormalities in Fibromyalgia and Chronic Fatigue Syndrome: New Concepts in Treatment
Current Pharmaceutical Design Is the Clinical Use of Cannabis by Oncology Patients Advisable?
Current Medicinal Chemistry Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology Current Status on Natural Products with Antitumor Activity from Brazilian Marine Sponges
Current Pharmaceutical Biotechnology Review on EGFR Inhibitors: Critical Updates
Mini-Reviews in Medicinal Chemistry Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)
Current Pharmacogenomics The Contractile Properties of Airway Smooth Muscle: How their Defects can be Linked to Asthmatic Airway Hyperresponsiveness?
Current Respiratory Medicine Reviews Pharmacogenomics in a Global World: A Roadmap for Australia, Prospects and Challenges
Current Pharmacogenomics and Personalized Medicine Editorial [Hot topic: Metal Chelation (Guest Editors: Paul V. Bernhardt & Des R. Richardson)]
Current Topics in Medicinal Chemistry